Posttransplant lymphoproliferative disorder in pediatric patients

Pathobiology

Volumn 80, Issue 6, 2013, Pages 289-296

  Hussein, Kais ^a   Tiede, Christina ^b   Maecker Kolhoff, Britta ^a,b   Kreipe, Hans ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Department of Prosthetic Dentistry and Biomedical Materials Science ^*  (Germany)

Author keywords

Posttransplant lymphoproliferative disorder; Prognostic factors; Solid organ transplantation

Indexed keywords

LACTATE DEHYDROGENASE; RITUXIMAB;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL PROLIFERATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS INFECTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCOMPETENCE; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MOLECULAR PATHOLOGY; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; TONSILLECTOMY; CANCER SURGERY; CHILDHOOD DISEASE; EPSTEIN BARR VIRUS; GRAFT REJECTION; MONOMORPHIC LYMPHOPROLIFERATIVE DISEASE; POLYMORPHIC LYMPHOPROLIFERATIVE DISEASE; VIRUS LATENCY; VIRUS PATHOGENESIS;

CHILD; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; PROGNOSIS; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 84883728861     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000350331     Document Type: Article

References (44)

1. Everly MJ, Bloom RD, Tsai DE, Trofe J: Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007; 41: 1850-1858.
2. Shroff R, Rees L: The post-transplant lymphoprolipherative disorder - a literature review. Pediatr Nephrol 2004; 19: 369-377.
3. Hussein K, Maecker-Kolhoff B, Klein C, Kreipe H: Transplant-associated lymphoproliferation. Pathologe 2011; 32: 152-158.
4. Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C, Haemato-Oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society: Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149: 675-692.
5. Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C, Haemato-Oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society: Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149: 693-705.
6. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM: Multicenter analysis of 80 solid organ transplantation recipients with posttransplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038-1046.
7. Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, Kirklin JK, Canter CE, Pediatric Heart Transplant Study: Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006; 367: 233-239.
8. Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, Hoyer P, Koepf S, Kraemer U, Laube GF, Müller-Wiefel DE, Netz H, Pohl M, Toenshoff B, Wagner HJ, Wallot M, Welte K, Melter M, Offner G, Klein C: CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007; 25: 4902-4908.
9. Mucha K, Foroncewicz B, Ziarkiewicz-Wróblewska B, Krawczyk M, Lerut J, Paczek L: Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 2010: 25: 2089-2098.
10. Luzuriaga K, Sullivan JL: Infectious mononucleosis. N Engl J Med 2010; 362: 1993-2000.
11. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052-2059.
12. Vakiani E, Nandula SV, Subramaniyam S, Keller CE, Alobeid B, Murty VV, Bhagat G: Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol 2007; 38: 315-325.
13. Vakiani E, Basso K, Klein U, Mansukhani MM, Narayan G, Smith PM, Murty VV, Dalla-Favera R, Pasqualucci L, Bhagat G: Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol 2008; 26: 199-211.
14. Rinaldi A, Kwee I, Poretti G, Mensah A, Pruneri G, Capello D, Rossi D, Zucca E, Ponzoni M, Catapano C, Tibiletti MG, Paulli M, Gaidano G, Bertoni F: Comparative genomewide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Br J Haematol 2006; 134: 27-36.
15. Rinaldi A, Capello D, Scandurra M, Greiner TC, Chan WC, Bhagat G, Rossi D, Morra E, Paulli M, Rambaldi A, Rancoita PM, Inghirami G, Ponzoni M, Moreno SM, Piris MA, Mian M, Chigrinova E, Zucca E, Favera RD, Gaidano G, Kwee I, Bertoni F: Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. Br J Haematol 2010; 149: 569-577.
16. Capello D, Rasi S, Oreste P, Veronese S, Cerri M, Ravelli E, Rossi D, Minola E, Colosimo A, Gambacorta M, Muti G, Morra E, Gaidano G: Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. J Pathol 2009; 218: 478-486.
17. Bredt M, Schönfeld G, Kleeberger W, König E, Kröning H, Kettner E, Al-Ali HK, Niederwieser D, Kreipe H: Late-onset Epstein-Barr virus (EBV)-negative extranodal B-precursor lymphoblastic lymphoma of donor origin after hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2003; 31: 1071-1072.
18. Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, Ansell SM, Gores GJ, Stegall MD, McGregor CG: Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005; 79: 244-247.
19. Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP: Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001; 20: 1054-1063.
20. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA: Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206-209.
21. Schober T, Framke T, Kreipe H, Schulz TF, Grohennig A, Hussein K, Baumann U, Pape L, Schubert S, Wingen AM, Jack T, Koch A, Klein C, Maecker-Kolhoff B: Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 2013; 95: 240-246.
22. Swerdlow SH, Webber SA, Chadburn A, Ferry JA: Post-transplant lymphoproliferative disorder; in Swerdlow SH, Campo E, Harris NL, et al (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 4. Lyon, IRAC, 2008, pp 343-351.
23. Caillard S, Lelong C, Pessione F, Moulin B: Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735-2742.
24. Trofe J, Buell JF, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG, Succop P, Woodle ES: Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5: 775-780.
25. Metzelder ML, Schober T, Grigull L, Klein C, Kuebler JF, Ure BM, Maecker-Kolhoff B: The role of laparoscopic techniques in children with suspected post-transplantation lymphoproliferative disorders. J Laparoendosc Adv Surg Tech A 2011; 21: 767-770.
26. Imadome KI, Fukuda A, Kawano F, Imai Y, Ichikawa S, Mochizuki M, Shigeta T, Kakiuchi T, Sakamoto S, Kasahara M, Fujiwara S: Effective control of Epstein-Barr virus infection following pediatric liver transplantation by monitoring of viral DNA load and lymphocyte surface markers. Pediatr Transplant 2012; 16: 748-757.
27. Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ: Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. J Clin Virol 2012; 53: 186-194.
28. Schiffer L, Henke-Gendo C, Wilsdorf N, Hussein K, Pape L, Schmitt C, Haller H, Schiffer M, Klein C, Kreipe H, Maecker-Kolhoff B: CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD. Am J Transplant 2012; 12: 1610-1607.
29. von Falck C, Maecker B, Schirg E, Boerner AR, Knapp WH, Klein C, Galanski M: Posttransplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring. Eur J Radiol 2007; 63: 427-435.
30. Boersma MN, van der Zanden A, Laverman GD, Sanders JS, de Vries PA: Epstein-Barr virus-positive post-transplant lymphoproliferative disorder of the central nervous system, after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid. Transpl Int 2012; 25:e113-116.
31. Shimizu H, Saitoh T, Koya H, Yuzuriha A, Hoshino T, Hatsumi N, Takada S, Nagaki T, Nojima Y, Sakura T: Discrepancy in EBVDNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Int J Hematol 2011; 94: 495-498.
32. van Krieken JH, Langerak AW, Macintyre EA, Kneba M, Hodges E, Sanz RG, Morgan GJ, Parreira A, Molina TJ, Cabeçadas J, Gaulard P, Jasani B, Garcia JF, Ott M, Hannsmann ML, Berger F, Hummel M, Davi F, Brüggemann M, Lavender FL, Schuuring E, Evans PA, White H, Salles G, Groenen PJ, Gameiro P, Pott Ch, Dongen JJ: Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007; 21: 201-206.
33. Tiede C, Maecker-Kolhoff B, Klein C, Kreipe H, Hussein K: Risk factors and prognosis in T-cell post-transplant lymphoproliferative diseases - re-evaluation of 163 cases. Transplantation 2013; 95: 479-488.
34. Ziarkiewicz-Wróblewska B, Górnicka B, Gierej B, Suleiman W, Nowacka-Cieciura E, Durlik M, Bogdańska M, Wasiutyński A, Pileri SA: Hodgkin-like lymphoma, simulating anaplastic large cell lymphoma in the patient after renal transplantation - unusual case report and literature review. Pol J Pathol 2008; 59: 63-69.
35. Morovic A, Jaffe ES, Raffeld M, Schrager JA: Metachronous EBV-associated B-cell and Tcell posttransplant lymphoproliferative disorders in a heart transplant recipient. Am J Surg Pathol 2009; 33: 149-154.
36. Rohr JC, Wagner HJ, Lauten M, Wacker HH, Jüttner E, Hanke C, Pohl M, Niemeyer CM: Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant 2008; 12: 426-431.
37. Shaknovich R, Basso K, Bhagat G, Mansukhani M, Hatzivassiliou G, Murty VV, Buettner M, Niedobitek G, Alobeid B, Cattoretti G: Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica 2006; 91: 1313-1320.
38. Jagadeesh D, Woda BA, Draper J, Evens AM: Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122-136.
39. van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J: Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 2008; 50: 886-888.
40. Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJ: Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group report. Am J Transplant 2012; 12: 3069-3075.
41. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network: Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
42. Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS: Hodgkin's lymphoma after posttransplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant 2004; 8: 87-90.
43. Bollard CM, Rooney CM, Heslop HE: T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9: 510-519.
44. Tai CC, Curtis JL, Szmuszkovicz JR, Horn MV, Ford HR, Woo MS, Wang KS: Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality. J Pediatr Surg 2008; 43: 2174-2177.